Coronary Laser in Undilatable or Uncrossable Lesions

Active, not recruitingOBSERVATIONAL
Enrollment

230

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

March 10, 2025

Study Completion Date

October 20, 2025

Conditions
Coronary Artery DiseaseCalcified Coronary Artery DiseaseIn Stent RestenosisChronic Total Occlusion (CTO)
Interventions
DEVICE

Laser atherectomy

"ELCA procedure will be performed using the Spectranetics CVX300 (Spectranetics, Colorado Spring, CO, USA) and the latest generation Philips Laser System Excimer (Philips, San Diego, CA, USA) System, which is based on pulsed xenon-chlorine laser catheters capable of delivering excimer energy (wavelength 308 nm, pulse length 185 ns) from 30 to 80 mJ/mm2 (fluencies) at pulse repetition rates from 25 to 80 Hz.~The ELCA technique will be performed according to current recommendations (18). The laser probe size will be at the operator´s discretion among the available options (rapid exchange concentric 0.9 mm, 1.4 mm, 1.7mm or 2.0mm). The selection of fluence, and repetition rate will be left to the operator. A saline infusion technique will be recommended, although application of laser with blood or contrast will be recommended in resistant lesions. In the event of unsuccessful initial therapy, additional plaque modification techniques may be employed at the discretion of the operator and wi"

Trial Locations (1)

Unknown

Hospital Universitario La Paz, Madrid

All Listed Sponsors
lead

Hospital Universitario La Paz

OTHER